David J. Wambeke - 10 Apr 2023 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role: Chief Business Officer
Signature: /s/ Amy Culbert, attorney-in-fact
Issuer symbol: DMAC
Transactions as of: 10 Apr 2023
Net transactions value: +$750,000
Form type: 4
Filing time: 11 Apr 2023, 17:40:11 UTC
Next filing: 26 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DMAC	Voting Common Shares, no par value per share	Purchase	$750,000	+468,750		$1.60	468,750	10 Apr 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DMAC	Stock Option (right to buy)	Award	$0	+140,000		$0.000000	140,000	10 Apr 2023	Common Shares	140,000	$1.57	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option vests with respect to 35,000 common shares on April 10, 2024 and with respect to the remaining 75% of the common shares in 12 as nearly equal as possible quarterly installments commencing three months after the one-year anniversary of the grant date.